What Fueled The Previous Growth In The Paroxysmal Nocturnal Hemoglobinuria PNH Market?
The paroxysmal nocturnal hemoglobinuria pnh market has seen considerable growth due to a variety of factors.
• There has been a swift increase in the market size of paroxysmal nocturnal hemoglobinuria (PNH) in the past few years. This market is projected to escalate from $4.24 billion in 2024 to $4.68 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.4%.
Factors such as heightened demand for PNH treatment, increase in disposable income, government policies, and higher healthcare spending propelled growth during the historic period.
How Does the Forecast Look for the Paroxysmal Nocturnal Hemoglobinuria PNH Market?
The paroxysmal nocturnal hemoglobinuria pnh market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for paroxysmal nocturnal hemoglobinuria (PNH) is projected to witness a robust increase in the upcoming years. It is expected to swell to a whopping $6.69 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.3%.
Factors propelling the growth during the forecast period include an older population, an escalating demand for self-regulated treatments, improved access to medical services, a rise in co-existing health conditions, and a surge in the demand for bespoke medicine. The forecast period will also see some major patterns like the implementation of digital health technologies, the advent of novel and innovative treatments, the growing acceptance of gene therapy, and the emphasis on early intervention.
What Are The Leading Drivers Of Growth In The Paroxysmal Nocturnal Hemoglobinuria PNH Market?
The surge in blood-related and bone marrow issues is set to bolster the paroxysmal nocturnal hemoglobinuria (PNH) market's development. Medical scenarios that affect the blood's structure, function, and generation are recognized as blood disorders. Disorders linked to bone marrow surge when the bone marrow fails to generate sufficient red or white cells, or platelets, or when the blood cells produced are damaged or defective. PNH has a close association with blood disorders and bone marrow ailments due to its influence on blood cell generation, the functioning of the immune system, and the microenvironment of the bone marrow. PNH is a rare blood ailment tied to bone marrow failure diseases and occurs when a genetic defect impacts the functioning of the red blood cells and platelets. For instance, according to Cancer Australia, a government agency based in Australia, around 5,202 new leukemia cases are expected in 2022, with 3,198 cases in males and 2,004 in females. An individual has a 1.7% (or 1 in 58) chance of getting diagnosed with leukemia by the age of 85. This risk is higher in males at 2.1% (or 1 in 47), compared to females with a risk of 1.3% (or 1 in 77). Therefore, the increase in blood and bone marrow-related disorders is fuelling the development of the paroxysmal nocturnal hemoglobinuria (PNH) market.
Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Driver: The Growing Need for Blood Transfusions Fuels The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market
How Are The Segments Defined Within The Global Paroxysmal Nocturnal Hemoglobinuria PNH Market?
The paroxysmal nocturnal hemoglobinuria (PNH) market covered in this report is segmented –
1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies, Management Of Complications
Pre-Book The Paroxysmal Nocturnal Hemoglobinuria PNH Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Paroxysmal Nocturnal Hemoglobinuria PNH Market?
Key players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) field are striving to maintain their market hold by creating novel drugs and therapeutic strategies, such as injectable C5 inhibitors for PNH treatment. Injectable C5 inhibitors, acting as monoclonal antibodies, hinder the activity of complement component C5, thus mitigating inflammation and tissue devastation in autoimmune disorders, including PNH. For example, Chugai Pharmaceutical Co., a pharmaceutical firm based in Japan, earned a primacy appraisal endorsement from the National Medical Products Administration (NMPA) of China in February 2024 for treating PNH. This accomplishment attests China to be the first nation to sanction PIASKY before any other primary marketplaces, consequently setting forth its entry into the National Reimbursement Drug List (NRDL) discussions within the same annum. With PNH being identified as a rare disorder affecting approximately 12,740 individuals in China, the market holds considerable potential.
Who Are the Key Players In The Paroxysmal Nocturnal Hemoglobinuria PNH Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are:
• Pfizer Inc.
• Johnson & Johnson Pvt Ltd.
• F. Hoffmann-La Roche AG.
• Novartis AG
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• GE Healthcare
• Regeneron Pharmaceuticals Inc.
• CSL Behring LLC
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Grifols S.A.
• Genentech Inc.
• Shire PLC
• Alnylam Pharmaceuticals Inc.
• Innovent Biologics Inc.
• Bioverativ Inc.
• CinnaGen Co
• BioCryst Pharmaceuticals
• Omeros Corporation
• Hansa Biopharma AB
• Apellis Pharmaceuticals Inc.
• Kira Pharmaceuticals Ltd.
• Akari Therapeutics PLC
• RA Pharmaceuticals Inc.
• C5 Therapeutics Inc.
What Is The Most Dominant Region In The Paroxysmal Nocturnal Hemoglobinuria PNH Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
